Invex Therapeutics Ltd (IXC.AX)

Invex Therapeutics Ltd (IXC.AX) — VMCI valuation read

Across 120 indicators, Invex Therapeutics Ltd (IXC.AX) lands at VMCI 51/100. The Healthcare sector median is 50, so the 1-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on IXC.AX in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, IXC.AX trades at 15.0x earnings, 17% below the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp. On Risk, net debt to EBITDA of 1.9x is the rate-sensitivity line to watch for IXC.AX on the trailing balance sheet.

IXC.AX rose 3.8% over the trailing 7 days, with a -18.8% read on a 30-day basis.